Entrada Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Entrada Therapeutics is a biopharmaceutical company developing therapies for neuromuscular and other diseases using its endosomal escape vehicle (EEV) platform, which delivers oligonucleotides and other molecules directly into cells and tissues to reach intracellular targets, including programs for Duchenne muscular dystrophy and myotonic dystrophy.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| MPM BioVentures 2014, L.P.Insider | Sell | $26K | 3,733at $7.01 | Aug 28, 2026 |
| MPM BIOVENTURES 2018, L.P.Insider | Sell | $309K | 44,259at $6.99 | Aug 31, 2026 |
| MPM BioVentures 2014, L.P.Insider | Sell | $309K | 44,259at $6.99 | Aug 31, 2026 |
| MPM BIOVENTURES 2018, L.P.Insider | Sell | $280K | 38,922at $7.20 | Aug 27, 2026 |
| MPM BioVentures 2014, L.P.Insider | Sell | $280K | 38,922at $7.20 | Aug 27, 2026 |
| MPM BIOVENTURES 2018, L.P.Insider | Sell | $26K | 3,733at $7.01 | Aug 28, 2026 |
| MPM BioVentures 2014, L.P.Insider | Sell | $200K | 26,522at $7.54 | Aug 25, 2026 |
| MPM BIOVENTURES 2018, L.P.Insider | Sell | $200K | 26,522at $7.54 | Aug 25, 2026 |
| MPM BioVentures 2014, L.P.Insider | Sell | $159K | 21,623at $7.34 | Aug 24, 2026 |
| MPM BIOVENTURES 2018, L.P.Insider | Sell | $159K | 21,623at $7.34 | Aug 24, 2026 |
| MPM BioVentures 2014, L.P.Insider | Sell | $103K | 14,569at $7.06 | Aug 26, 2026 |
| MPM BIOVENTURES 2018, L.P.Insider | Sell | $103K | 14,569at $7.06 | Aug 26, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable TRDA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.